Elevance Health (NYSE:ELV – Free Report) had its price target increased by Wells Fargo & Company from $557.00 to $600.00 in a research report sent to investors on Friday, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock. Several other research firms have also recently issued reports on ELV. Royal […]